Several selective TRK inhibitors have more recently entered clinical development and are in Phase I or Phase I/II clinical trials, as shown in the table below.
There are also drugs already approved or in clinical development that are multikinase inhibitors with anti-TRK activity. These are being trialed in tumour types where NTRK gene fusions may play a role but not all of these trials require patients to have tumours with NTRK gene fusion. Such relevant trials that are currently ongoing are shown below.
